Regeneron Pharmaceuticals Inc reports a single dose of its antibody drug lowered the risks of COVID-19 by 81.6%, according to a report by a press release by Regeneron on Monday.  

  • Myron Cohen, U.S. National Institutes of Health-sponsored COVID-19 Prevention Network leader stated that findings showed that antibody therapy, REGEN-COV, has the ability to provide long-term immunity from COVID-19 infection.
  • Such immunity is more so vital for immunocompromised people and those not responding to the vaccines.
  • The therapy had initially indicated an 81.4% risk reduction during the first month after administration.
  • During the 8-month assessment duration, there were cases of hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such cases were documented.

The U.S. health regulatory in July expanded the authorization of REGN-COV to improve its use as a preventive treatment in people diagnosed with COVID-19 and those at high risk of exposure. RGBP up +7.12%